Alchemia kicks off phase II lung cancer trial
09 September, 2011 by Staff WritersA phase II trial of anti-cancer drug, HA-Irinotecan, for the treatment of small cell lung cancer, has commenced in Melbourne.
Feature: Building better drugs
07 September, 2011 by Fiona WylieEureka Award winner, Associate Professor Kevin Pfleger, straddles the worlds of academia and biotechnology, helping to apply his findings for the lab to producing better drugs.
Immuron moves to human trials for influenza drug
30 August, 2011 by Staff WritersPhase I/IIa human trials for Immuron’s (ASX:IMC) IMM 255 immunotherapy for influenza will take place in Israel.
QRxPharma advances with NDA for MoxDuo IR
25 August, 2011 by Staff WritersQRxPharma (ASX:QRX) has completed its New Drug Application submission with the FDA, one of the last hurdles before being given regulatory approval.
Feature: Genetics and the origins of modern cotton
24 August, 2011 by Graeme O'NeillProfessor Jonathan Wendel is retracing the genetic changes to cotton that have occurred over more than 5000 years of domestication.
R&D Tax Credit clears Senate
23 August, 2011 by Tim DeanThe much-debated and long-delayed R&D Tax Credit has been given the go-ahead by the Senate, although it still needs to go through the House of Representatives for any amendments.
Cochlear posts 16% jump in profit for FY11
09 August, 2011 by Tim DeanProving that market jitters don’t necessarily reflect underlying profitability, Cochlear has posted a 10% increase in revenue and 16% jump in profit for FY11.
Market watch: Biotechs take battering as markets lurch
08 August, 2011 by Tim DeanBiotechnology stocks haven’t been spared the tumult of the market with several falls of over 5% today.
Bionomics to extend trials of ovarian cancer treatment
04 August, 2011 by Staff WritersTrials of BNC105 in combination with existing chemotherapy drugs to treat ovarian cancer.
Vaxxas gets $15m injection to develop needle-free vaccine
02 August, 2011 by Tim DeanBiotech start-up Vaxxas has received a $15m venture capital kick start to commercialise needle-free vaccine delivery system Nanopatch.
Plasvacc pulls out of sale to Bioniche
02 August, 2011 by Tim DeanThe proposed acquisition of Plasvacc by Bioniche has been kyboshed, with Plasvacc walking away from the deal after negotiations "collapsed".
Feature: Biosecurity and animal-borne viruses
27 July, 2011 by Fiona WylieCSIRO’s Dr Lin-Fa Wang works in the depths of a national biosecurity facility jam-packed with some of the planet’s nastier viruses that call bats home.
Feature: Battling Hendra virus
27 July, 2011 by Fiona WylieOver the last 15 years, Dr Lin-Fa Wang ‘s group has quadrupled in size and now works on many different aspects of bat biology.
New hope for treatment of Ross River fever
25 July, 2011 by Tim DeanA discovery by scientists at Griffith University’s Institute for Glycomics opens the possibility of a new treatment for viruses that cause inflammation, such as Ross River virus and Dengue Fever.
Ian Frazer partners with US university on DNA vaccine
20 July, 2011 by Tim DeanCoridon and Ohio State University have begun collaborating on testing Coridon’s DNA vaccine for Epstein Barr Virus for the prevention of lymphoproliferative disease.
